Lan Xiaopeng, Feng Mei, Chen Lili, Zhang Luchen, Han Chao, Wang Yizhen, Zheng Jilu, Wang Xiaoyan, Liu Chunlei, Liu Ranlu
Department of Urology, Tianjin Medical University General Hospital, Tianjin, China.
Department of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266042, People's Republic of China.
Discov Oncol. 2024 Aug 23;15(1):366. doi: 10.1007/s12672-024-01249-w.
Increasing research efforts are focused on studying the synthesis and mechanisms of nanomedicine in urologic cancer. We performed a bibliometric study of the literature on nanomedicine in urologic cancer over the last 23 years, focusing on aspects such as researchers, institutions, nations, and keywords. We searched for papers in the Web of Science Core Collection from January 1, 2001, to December 29, 2023. Only reviews and original articles written in English were considered. A total of 2386 papers satisfied the given criteria for inclusion. The publications included in the study originated from 90 nations. The United States had the largest number of published papers, accounting for more than 31.01% of the total. The leading institution in this field is the Chinese Academy of Sciences, with a publishing output of 2.35%. Farokhzad, Omid C., is the most prolific author, with 21 articles, and has garnered the most citations, totaling 6271. The latest phrase to enter the top ten most common lists was "gold nanoparticles." We searched for papers in the Web of Science Core Collection from January 1, 2000, to November 28, 2023. Only reviews and original articles written in English were considered. This is the first bibliometric study of nanomedicine in urologic cancer. This article provides a comprehensive analysis of the current state of research on nanomedicine in urologic cancer over the last 23 years. On the basis of this study, future researchers can identify noteworthy publications, journals, and potential collaborators and explore cutting-edge research directions.
Front Biosci (Landmark Ed). 2022-8-31
Front Mol Biosci. 2024-7-29
Drug Deliv Transl Res. 2024-6
Front Aging Neurosci. 2023-5-16
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023-10-20
Front Genet. 2024-4-12
Urol Oncol. 2024-4
Lancet Oncol. 2024-2
Arch Toxicol. 2024-2
Crit Rev Oncol Hematol. 2023-12
Nat Rev Cancer. 2023-9-8
Plants (Basel). 2023-5-3
CA Cancer J Clin. 2023-1
J Nanobiotechnology. 2023-1-3
Biosensors (Basel). 2022-9-27